Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?

finance.yahoo.com · 2026-09-10

Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.

TickrTrends take: Amgen trades at a valuation that TickrTrends currently rates as overvalued, which suggests investors focused on value metrics may want to monitor whether the company's fundamentals improve enough to justify its current price before committing capital. The comparison with Moderna reflects ongoing competitive dynamics in the healthcare sector, though valuation assessments require examining each company's specific metrics rather than relative positioning alone. For those tracking valuation trends, movement in Amgen's overvalued status will depend on factors such as earnings growth, pipeline developments, and market multiples adjusting over time.

Read the full story at finance.yahoo.com →